Kenneth Tsai, MD, PhD, FCAP, discusses a study for combating aggressive Merkel cell carcinoma. “Our findings not only highlight the potential to use specific genes and immune cells as biomarkers for predicting patient response to immune checkpoint blockade therapy, but also suggest several approaches for abrogating resistance and enhancing efficacy,” said Dr. Tsai.
For the full article click here: Study uncovers key immune cells for combating aggressive Merkel cell carcinoma